Pfizer (PFE) Operating Expenses (2009 - 2026)

Pfizer (PFE) has reported Operating Expenses for 18 consecutive years, with $6.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 14.67% year-over-year to $6.7 billion in Q2 2026; TTM through Jun 2026 was $26.2 billion, a 33.31% decrease from a year earlier, with the FY2025 full-year figure at $25.8 billion, down 7.83% from the prior year.
• Operating Expenses was $6.7 billion for Q2 2026 at Pfizer, up from $5.6 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $19.9 billion in Q3 2024 and troughed at $5.1 billion in Q2 2022.
• A 5-year average of $7.5 billion and a median of $6.1 billion in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses gained 20.57% in 2024 and tumbled 69.78% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $6.1 billion in 2022, then surged by 64.51% to $10.0 billion in 2023, then soared by 100.0% to $19.9 billion in 2024, then slumped by 59.96% to $8.0 billion in 2025, then fell by 16.25% to $6.7 billion in 2026.
• The last three Operating Expenses figures came in at $6.7 billion (Q2 2026), $5.6 billion (Q1 2026), and $8.0 billion (Q4 2025), per Business Quant data.